
EndoPredict® is a second-generation 12 gene molecular assay designed for patients with early-stage (Stage I–III), ER-positive/HER2-negative breast cancer. It predicts the risk of distant recurrence and helps assess the potential benefit of adjuvant chemotherapy.
Genomic data generated by the test are combined with clinical parameters, including tumor size and lymph node status, to calculate the EPclin® score.

EndoPredict:
| Feature | Details |
|---|---|
| Cancer Type | Early-Stage Breast Cancer (ER+, HER2−) |
| Recommended For |
|
| Sample Type | Tumor Tissue (FFPE) |
| Method | Real-Time qPCR |
| Genomic Signature | 12-Gene Molecular Score (EPclin®) |
| Turnaround Time | 2–3 Weeks |
19 Mayıs Mah. Çoruh Sok. No:32/1 Fulya, 34394 Şişli / Istanbul, Turkey
Monday - Friday 09:00 - 18:00 Saturday 09:00 - 14:00